Halozyme Therapeutics Inc (HALO) · Peers
Halozyme Therapeutics against the 105 other companies here in its SEC industry, Biological Products, (No Diagnostic Substances). Each figure is the one on the company's own page; the median is the peers', and the rank is among all 106, highest first.
Measure by measure
| Measure | HALO | Peer median | Rank |
|---|---|---|---|
| Market value | $13.83B | median $252.43M | 9 of 105 |
| P/E | 43.6× | median 21.6× | 5 of 19 |
| Forward P/E | 13.8× | median 18.8× | 13 of 18 |
| EV/EBITDA | 32.7× | median 16.1× | 7 of 19 |
| P/S | 8.3× | median 7.3× | 44 of 92 |
| FCF yield | 5.8% | median -20.8% | 9 of 105 |
| Gross margin | 82.4% | median 69.2% | 14 of 50 |
| Operating margin | 28.2% | median -122.9% | 9 of 73 |
| Net margin | 19.0% | median -96.6% | 12 of 67 |
| ROIC | 17.2% | median -61.4% | 10 of 51 |
| ROE | 220.8% | median -45.2% | 1 of 86 |
| Revenue growth (4y, yearly) | 33.2% | median -0.5% | 18 of 80 |
| EPS growth (yearly) | -1.7% | median 8.3% | 5 of 8 |
| Net debt / EBITDA | 4.2× | median 0.8× | 2 of 7 |
| Current ratio | 2.7× | median 4.9× | 74 of 106 |
| Stock pay / revenue | 3.8% | median 21.0% | 74 of 87 |
| Share count change | -4.3% | median 13.8% | 101 of 102 |
Green where Halozyme Therapeutics is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| HALOHalozyme Therapeutics Inc | $13.83B | P/E 43.6× | 17.2% | 5.8 |
| AMGNAmgen Inc | $233.82B | P/E 26.7× | 14.9% | 5.2 |
| GILDGilead Sciences Inc | $193.67B | P/E – | -5.3% | 4.5 |
| MRNAModerna, Inc. | $87.04B | P/E – | -116.5% | 2.8 |
| ARGXargenx NV ADR | $50.69B | P/E 39.2× | 21.5% | 6.0 |
| BNTXBioNTech SE | $44.22B | P/E – | -24.2% | 4.1 |
| RVMDRevolution Medicines, Inc. | $38.14B | P/E – | – | 2.9 |
| BIIBBiogen Inc | $34.35B | P/E 25.0× | 6.2% | 5.3 |
| EXELExelixis Inc | $15.42B | P/E 17.9× | 76.4% | 8.0 |
| NBIXNeurocrine Biosciences Inc | $13.79B | P/E 19.6× | 19.0% | 7.1 |
| TECHBIO-TECHNE Corp | $11.36B | P/E 154.8× | 3.9% | 4.5 |
| QGENQiagen NV | $10.01B | P/E 23.6× | 8.5% | 5.9 |
| RGENRepligen Corp | $9.90B | P/E 238.3× | 2.8% | 4.2 |
| IBRXImmunityBio, Inc. | $9.73B | P/E – | – | 4.5 |
| KRYSKrystal Biotech, Inc. | $9.37B | P/E 38.8× | 30.4% | 6.5 |
| KYMRKymera Therapeutics, Inc. | $8.71B | P/E – | -33.7% | 3.8 |
| IOVAIovance Biotherapeutics, Inc. | $6.17B | P/E – | -54.2% | 4.0 |
| SRRKScholar Rock Holding Corp | $4.86B | P/E – | – | 3.0 |
| CRSPCRISPR Therapeutics AG | $4.76B | P/E – | – | 4.2 |
| ADPTAdaptive Biotechnologies Corp | $3.83B | P/E – | – | 4.3 |
| RLAYRelay Therapeutics, Inc. | $3.57B | P/E – | -31.9% | 3.5 |
| TARSTarsus Pharmaceuticals, Inc. | $2.99B | P/E – | – | 5.4 |
| DNLIDenali Therapeutics Inc. | $2.81B | P/E – | -329.1% | 3.0 |
| BEAMBeam Therapeutics Inc. | $2.42B | P/E – | -2021.5% | 4.1 |
| ADMAAdma Biologics, Inc. | $2.39B | P/E 14.2× | 37.5% | 6.8 |
| VCELVericel Corp | $2.05B | P/E 84.8× | 4.2% | 5.5 |
| BCRXBiocryst Pharmaceuticals Inc | $1.99B | P/E – | – | 6.5 |
| NVAXNovavax Inc | $1.86B | P/E – | – | 3.6 |
| RXRXRecursion Pharmaceuticals, Inc. | $1.85B | P/E – | -112.1% | 3.7 |
| MESOMesoblast Ltd | $1.72B | P/E – | – | 3.5 |
| VIRVir Biotechnology, Inc. | $1.69B | P/E – | -48.8% | 4.5 |
| ALVOAlvotech | $1.56B | P/E 55.9× | 6.2% | 3.5 |
| IMCRImmunocore Holdings plc | $1.51B | P/E – | – | 5.4 |
| TSHATaysha Gene Therapies, Inc. | $1.18B | P/E – | – | 3.5 |
| VALNValneva SE | $973.77M | P/E – | -31.8% | 2.9 |
| MGTXMeiraGTx Holdings plc | $891.28M | P/E 11.3× | 148.9% | 7.0 |
| ODTXOdyssey Therapeutics, Inc. | $825.16M | P/E – | – | 4.9 |
| FDMT4D Molecular Therapeutics, Inc. | $670.30M | P/E – | -236.3% | 4.9 |
| DNAGinkgo Bioworks Holdings, Inc. | $654.31M | P/E – | -285.8% | 4.4 |
| PRMEPrime Medicine, Inc. | $629.38M | P/E – | – | 3.7 |
| DBVTDBV Technologies S.A. | $568.78M | P/E – | – | 2.9 |
And 65 smaller ones.
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.